U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...

Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

23andMe struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, ...

"It's cool to get the award, but what I submitted to it is so much more important to me," Cooper Taylor said about getting a ...

Kiniksa Pharmaceuticals sees strong growth from Arcalyst, aided by Medicare redesign. Learn about 2025 sales outlook & ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

Former CEO Anne Wojcicki has prevailed in the bankruptcy auction of 23andMe, its consumer and biopharma research businesses, ...

If approved by the court, the 23andMe sale would put Anne Wojcicki back at the helm of the company she co-founded and previously attempted to take private.